AZAstrid Zobel

Astrid Zobel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Astrid Zobel has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder

    by Anna Schuhmacher, Rainald Mössner, Susanne Höfels, Ute Pfeiffer, Vera Guttenthaler, Michael Wagner, Sibylle G. Schwab, Wolfgang Maier, Astrid Zobel

    Variant rs2522833 of the Piccolo-encoding gene PCLO has recently been found to be associated with major depressive disorder (MDD). PCLO encodes a pre


  • Open Access

    DNA sequence variants of the FKBP5 gene are associated with unipolar depression

    by Astrid Zobel, Anna Schuhmacher, Frank Jessen, Susanne Höfels, Olrik von Widdern, Martin Metten, Ute Pfeiffer, Claudia Hanses, Tim Becker, Marcella Rietschel, et al.

    FKBP5 is a glucocorticoid receptor-regulating co-chaperone of hsp-90 and, therefore, is suggested to play a role in the regulation of the hypothalami


  • Open Access

    Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial

    by Nader Perroud, Rudolf Uher, Andrej Marusic, Marcella Rietschel, Ole Mors, Neven Henigsberg, Joanna Hauser, Wolfgang Maier, Daniel Souery, Anna Placentino, et al.

    Suicidal thoughts and behaviours during antidepressant treatment, especially during the first weeks of treatment, have prompted warnings by regulatory bodies. The aim of the present study is to investigate the course and predictors of emergence and worsening of suicidal ideation during tricyclic antidepressant and serotonin reuptake inhibitor treatment. In a multicentre part-randomised open-label study, 811 adult patients with moderate to severe unipolar depression were allocated to flexible dosage of escitalopram or nortriptyline for 12 weeks. The suicidality items of three standard measures were integrated in a suicidal ideation score. Increases in this score were classified as treatment emergent suicidal ideation (TESI) or treatment worsening suicidal ideation (TWOSI) according to the absence or presence of suicidal ideation at baseline. Suicidal ideation decreased during antidepressant treatment. Rates of TESI and TWOSI peaked in the fifth week. Severity of depression predicted TESI and TWOSI. In men, nortriptyline was associated with a 9.8-fold and 2.4-fold increase in TESI and TWOSI compared to escitalopram, respectively. Retirement and history of suicide attempts predicted TWOSI. Increases in suicidal ideation were associated with depression severity and decreased during antidepressant treatment. In men, treatment with escitalopram is associated with lower risk of suicidal ideation compared to nortriptyline. Clinicians should remain alert to suicidal ideation beyond the initial weeks of antidepressant treatment. EudraCT (No.2004-001723-38) and ISRCTN (No. 03693000).


  • Changes in regional cerebral blood flow by therapeutic vagus nerve stimulation in depression: An exploratory approach

    by Astrid Zobel, Alexius Joe, Nikolaus Freymann, Hans Clusmann, Johannes Schramm, Michael Reinhardt, Hans-Jürgen Biersack, Wolfgang Maier, Karl Broich


  • Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy

    by Astrid Zobel, Jörg Wellmer, Svenja Schulze-Rauschenbach, Ute Pfeiffer, Susanne Schnell, Christian Elger, Wolfgang Maier

    Excess comorbidity between depression and epilepsy proposes common pathophysiological patterns in both disorders. Neuroendocrine abnormalities were often observed in depression as well as in epilepsy. Lack of inhibitory control of the hypothalamic pituitary adrenocortical (HPA) system is a core feature of depression; main relay stations of this system are located in the amygdala and hippocampus, which are key regions for both disorders. Therefore we explored the feedback mechanism of the HPA system in epilepsy. In order to control for the impact of depression we focused on epilepsies without depression. We compared patients with epilepsy (subdivided by medication with or without hepatic enzyme inducing antiepileptic medication) with 16 healthy controls and 16 patients with unipolar major depression but without epilepsy. We observed a lack of inhibitory control of the HPA system in patients with epilepsy, also in the absence of enzyme inducing medication. An impact of the temporal lobe location of the epileptic focus could not be observed. Thus, epilepsies share with depression the deficiencies in the feedback mechanism of the HPA system, proposing common pathophysiological features of up to now unknown nature.


  • Improvement of working but not declarative memory is correlated with HPA normalization during antidepressant treatment

    by Astrid W Zobel, Svenja Schulze-Rauschenbach, Olrik C von Widdern, Martin Metten, Nikolaus Freymann, Katja Grasmäder, Ute Pfeiffer, Susanne Schnell, Michael Wagner, Wolfgang Maier


  • Endophänotypen—ein neues Konzept zur biologischen Charakterisierung psychischer Störungen

    by A. Zobel, W. Maier

    Das Konzept "Endophänotyp" hat in der psychiatrischen Genetik derzeit eine hohe Popularität. Die gegenwärtigen Schwierigkeiten bei der Suche nach Suszeptibilitätsgenen für komplexe Erkrankungen wird auf die ätiologische Heterogenität des klinischen, psychopathologisch definierten Krankheitsphänotyps zurückgeführt. Neurobiologische Krankheitskorrelate, die stabil über die Zeit sind und genetisch beeinflusst sind, werden statt dessen als erfolgversprechendere Zielphänotypen betrachtet, da sie von den unmittelbaren Geneffekten direkter beeinflusst sind und vermutlich einer weniger komplexen genetischen Determination unterliegen als der Krankheitsphänotyp. Die Endophänotypstrategie war in anderen Bereichen der Medizin bei komplexen Erkrankungen, aber auch bei Alkoholismus und spät beginnender Alzheimer-Erkrankung, erfolgreich. Bei der Schizophrenie ist eine Serie von Endophänotypen für die molekulargenetische Untersuchung vorgeschlagen worden. Daneben kann das Konzept des Endophänotyps aber auch eine Grundlage für die biologische Klassifikation psychischer Störungen bieten. In the field of psychiatric genetics, the concept of endophenotypes is presently receiving high popularity. Current difficulties in the search for susceptibility genes of complex diseases have been attributed to the etiological heterogeneity of the clinical, psychopathologically defined phenotype of the disease. Neurobiological correlates of the disease which are genetically influenced and stable over time are considered to be more promising targets of phenotypes. They are more directly influenced by gene effects and presumably defined by a genetic determination which is less complex than the phenotype of the disorder. The endophenotype strategy has already been successful in complex disorders of other areas in medicine, including alcoholism and late-onset Alzheimer's disease. For schizophrenia, a series of endophenotypes for molecular/genetic investigation has been suggested, but the concept "endophenotype" also provides a basis for biological classification of mental disorders.